PRAX News and Press, Praxis Precision Medicines Inc. From 06/06/22

Clinical-stage biotech Praxis Precision Medicines (NASDAQ:PRAX) announced plans to reduce its staff and operating expenses on Monday after its lead candidate PRAX-114 failed as monotherapy in a Phase 2/3 trial for major depressive disorder (MDD). The trial was designed to evaluate PRAX-114 as...

Aria Study did not achieve statistical significance on the primary endpoint Strategic realignment to focus resources on Movement Disorders and Epilepsy franchises extends cash runway into 2024 BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. ...

Gainers: Zoom Video Communications (ZM) +7%. Praxis Precision Medicines (PRAX) +5%. VNET Group (VNET) +4%. ACV Auctions (ACVA) +4%. Lixiang Education Holding Co (LXEH) +3%. Losers: Meta Platforms (FB) -8%. The Trade Desk (TTD) -7%. Magnite (MGNI) -6%. Nkarta (NKTX) -5%. Roku (ROKU) ...

BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition...

Gainers: Data Storage Corporation (DTST) +40%. Indonesia Energy Corporation (INDO) +30%. Harpoon Therapeutics (HARP) +28%. Pulse Biosciences (PLSE) +24%. Praxis Precision Medicines (PRAX) +24%. Xeris Biopharma Holdings (XERS) +24%. Griffon Corporation (GFF) +22%. New Concept Energy (GBR) +20%...

The following slide deck was published by Praxis Precision Medicines, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Praxis Precision Medicines, Inc. 2022 Q1 - Results - Earnings Call Presentation

Praxis Precision Medicines, Inc. (PRAX) Q1 2022 Earnings Conference Call May 9, 2022, 4:30 PM ET Company Participants Marcio Souza – President and Chief executive Officer Bernard Ravina – Chief Medical Officer Alex Kane – Vice President Investor Relations and Corporate Co...

Praxis Precision Medicines press release (NASDAQ:PRAX): Q1 GAAP EPS of -$1.51 misses by $0.21. As of March 31, 2022, Praxis had $222.5 million in cash, cash equivalents and marketable securities, compared to $275.9 million in cash, cash equivalents and marketable securities as of December 31,...

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results expected in June 2022 Epilepsy Day showcases largest targeted epilepsy por...

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was 42% as measured by Modified ADL, followed by statistically significant difference in the placebo-controlled randomized withd...